Company Profile
Verge Medical is a US-based manufacturer of coronary and peripheral vascular intervention devices, headquartered in Campbell, California, USA. Originally founded as Ostial Corporation in 2008 by Fred Khosravi, the company rebranded to Verge Medical in March 2025 and operates as an independent, privately-held entity and Incept LLC portfolio company, serving interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and select global markets.
Core Products ＆ Technologies
Aorto-Ostial Angioplasty Systems
• FLASH™ Aorto-Ostial Angioplasty System: The first and only dual balloon-based system designed for aorto-ostial angioplasty in coronary and peripheral cases, enabling 360° lesion coverage for streamlined vessel reaccess; used in over 25,000 procedures
• FLASH Flex™ Aorto-Ostial Angioplasty System: FDA 510(k) cleared in April 2026 (K254022); rapid exchange dual balloon catheter with enhanced tip flexibility, Fluorosaver™ markers, and pressure relief for post-delivery expansion of balloon-expandable stents within the coronary vasculature
Peripheral Embolic Protection
• RoVo™ System: FDA-cleared embolic protection device acquired in June 2025; utilizes patented Temporary Occlusion Embolectomy (TOE) technology to block downstream flow and capture debris during atherectomy and other peripheral interventions
Venous Infusion Catheters
• Wavella™ Specialty Infusion Catheter: Investigational device acquired in March 2025; employs a rotating sinusoidal wire to simultaneously deliver physician-specified agents for comprehensive, segmental agent delivery in the peripheral vasculature
Market Position ＆ Certifications
Verge Medical holds a specialized position in the global aorto-ostial and peripheral vascular intervention market, competing with Boston Scientific and Medtronic in balloon angioplasty and embolic protection. Key strengths include:
• 18+ years of US engineering heritage in vascular access and intervention
• Dual balloon technology: Unique proximal anchoring and distal dilatation design for aorto-ostial lesions
• Regulatory compliance: FDA 510(k) cleared (FLASH, FLASH Flex, RoVo); manufactured under quality system regulations
• Physician-driven innovation: Portfolio designed to address persistent gaps in coronary and peripheral procedural efficiency and safety
Corporate Timeline
2008 — Founded by Fred Khosravi as Ostial Corporation in California to address challenges of aorto-ostial stenting
2015 — FDA 510(k) clearance granted for FLASH Mini Ostial System (K152485) for peripheral and coronary vasculature
2020 — Passed 15,000 commercial units sold milestone across over 300 hospitals in the United States
2023 — Closed $7.5M Series C financing led by Delos Capital with participation from AMED Ventures
2024 — Mike Buck appointed Chief Executive Officer, bringing 30+ years of cardiovascular industry experience
2025 — Rebranded as Verge Medical; acquired Wavella technology from Crossfire Medical; acquired RoVo System from 2MG Medical
2026 — FDA 510(k) clearance granted for FLASH Flex™ Aorto-Ostial Angioplasty System (K254022)
Target Markets ＆ Applications
• Coronary aorto-ostial disease: FLASH systems for post-delivery stent expansion and lesion dilatation in coronary vasculature
• Peripheral arterial disease: RoVo System for distal embolic protection during atherectomy and peripheral interventions
• Venous therapy: Wavella catheter for segmental pharmacological agent delivery in peripheral venous applications
Contact Information
Global Headquarters
Address: 747 Camden Avenue, Suite A, Campbell, CA 95008, USA
Phone: 844-352-7411
Parent Company
Verge Medical operates as an independent, privately-held entity and Incept LLC portfolio company with no publicly traded stock.
Website: vergemedical.com
Investor Relations: Private company; backed by Delos Capital and AMED Ventures
